Fig. 3From: The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and ChinaIncidence rate reduction of RR/MDR-TB by 50% efficacy, 10-year duration of protection pre- and post-infection efficacy (P&PI) and post-infection efficacy (PSI) vaccines in India (top) and China (bottom). Lines represent median model incidence rate; ribbons represent model uncertainty. Vaccine is introduced in 2027Back to article page